June 26, 2019
Bristol-Myers Squibb said on June 24 that the anti-PD-1 antibody Opdivo (nivolumab) failed to demonstrate a statistically significant improvement in overall survival (OS) in comparison with sorafenib, a current standard of care, as a first-line treatment in unresectable hepatocellular carcinoma...read more